Eton Pharmaceutical ETON 深 滬
已收盤 08-15 16:00:00 美东时间
17.04
+0.340
+2.04%
華盛通- 最 高17.275
- 今 開16.75
- 成交量 36.73万股
- 最 低 16.27
- 昨 收 16.70
- 總市值 4.57亿
- 52周最高 21.48
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 4.4401
- 委 比 -60.78%
- 總股本 2681.75万
- 歷史最高 21.48
- 量 比 0.79
- 振 幅 6.02%
- 歷史最低 1.95
- 每 手 1
- 風險率 4.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palatin Announces 1-for-50 Reverse Stock Split
PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50. Th...
08-09 04:00
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results.
Eton Pharmaceuticals shares are trading higher after the company reported bette...
08-08 05:06
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Soligenix Completes Phase 2a Proof Of Concept Study Evaluating SGX945 In Behçet's Disease, Showing Biological Efficacy
PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
07-31 19:37
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Eton Pharmaceuticals, Inc. announced it will report second quarter 2025 financial results on August 7, 2025, with a conference call and live webcast at 4:30 p.m. ET. Participants can join by dialing (800) 715-9871 or (646) 307-1963 with conference ID 5899895 or via webcast. Investors can submit questions via email to investorrelations@etonpharma.com. The webcast will be available on Eton’s website, with an archived version posted two hours post-e...
07-28 11:00
Eton gains as hormonal disorder therapy undergoes FDA review
Shares of Eton Pharmaceuticals (NASDAQ:ETON) added ~8% in the premarket on Tuesday after the FDA agreed to review its marketing application for ET-600, a potential treatment for a rare hormonal disord...
07-08 19:33
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
PRINCETON, N.J., July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing prod...
07-08 19:30
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals announced the FDA acceptance of its New Drug Application (NDA) for ET-600, a proprietary desmopressin oral solution for treating central diabetes insipidus (AVP-D). The FDA has set a target action date of February 25, 2026, and the product is patented through 2044. ET-600 addresses a significant unmet need by offering an accurate, titratable liquid solution for pediatric patients. Eton has initiated commercial preparations fo...
07-08 10:50
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and...
07-02 19:00
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Active Ingredient Manufacturing Transfer to the U.S. Complete PRINCETON, N.J., July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharma...
07-01 19:30
